258 related articles for article (PubMed ID: 8995552)
1. A randomized trial of paracentesis plus intraperitoneal tumor necrosis factor-alpha versus paracentesis alone in patients with symptomatic ascites from recurrent ovarian carcinoma.
Hirte HW; Miller D; Tonkin K; Findlay B; Capstick V; Murphy J; Buckman R; Carmichael J; Levine M; Hill W
Gynecol Oncol; 1997 Jan; 64(1):80-7. PubMed ID: 8995552
[TBL] [Abstract][Full Text] [Related]
2. Intraperitoneal pressures and clinical parameters of total paracentesis for palliation of symptomatic ascites in ovarian cancer.
Gotlieb WH; Feldman B; Feldman-Moran O; Zmira N; Kreizer D; Segal Y; Elran E; Ben-Baruch G
Gynecol Oncol; 1998 Dec; 71(3):381-5. PubMed ID: 9887235
[TBL] [Abstract][Full Text] [Related]
3. Current and future options in the treatment of malignant ascites in ovarian cancer.
Woopen H; Sehouli J
Anticancer Res; 2009 Aug; 29(8):3353-9. PubMed ID: 19661355
[TBL] [Abstract][Full Text] [Related]
4. Clinical Trial: High-dose furosemide plus small-volume hypertonic saline solutions vs. repeated paracentesis as treatment of refractory ascites.
Licata G; Tuttolomondo A; Licata A; Parrinello G; Di Raimondo D; Di Sciacca R; Cammà C; Craxì A; Paterna S; Pinto A
Aliment Pharmacol Ther; 2009 Aug; 30(3):227-35. PubMed ID: 19438847
[TBL] [Abstract][Full Text] [Related]
5. Unsuspected infection is infrequent in asymptomatic outpatients with refractory ascites undergoing therapeutic paracentesis.
Jeffries MA; Stern MA; Gunaratnam NT; Fontana RJ
Am J Gastroenterol; 1999 Oct; 94(10):2972-6. PubMed ID: 10520854
[TBL] [Abstract][Full Text] [Related]
6. Intraperitoneal infusion of recombinant human tumor necrosis factor and mitoxantrone in neoplastic ascites: a feasibility study.
Del Mastro L; Venturini M; Giannessi PG; Vigani A; Garrone O; Carnino F; Russo P; Galletti P; Rosso R; Conte PF
Anticancer Res; 1995; 15(5B):2207-12. PubMed ID: 8572626
[TBL] [Abstract][Full Text] [Related]
7. Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites.
Räth U; Kaufmann M; Schmid H; Hofmann J; Wiedenmann B; Kist A; Kempeni J; Schlick E; Bastert G; Kommerell B
Eur J Cancer; 1991; 27(2):121-5. PubMed ID: 1827272
[TBL] [Abstract][Full Text] [Related]
8. Intraperitoneal interferon-alpha in residual ovarian carcinoma: a phase II gynecologic oncology group study.
Berek JS; Markman M; Stonebraker B; Lentz SS; Adelson MD; DeGeest K; Moore D
Gynecol Oncol; 1999 Oct; 75(1):10-4. PubMed ID: 10502418
[TBL] [Abstract][Full Text] [Related]
9. Salvage weekly paclitaxel in recurrent ovarian cancer.
Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study.
Feun LG; Blessing JA; Major FJ; DiSaia PJ; Alvarez RD; Berek JS
Gynecol Oncol; 1998 Dec; 71(3):410-5. PubMed ID: 9887240
[TBL] [Abstract][Full Text] [Related]
11. Treatment of patients with upper gastrointestinal carcinomas.
Ajani JA
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-72-S19-76. PubMed ID: 9427271
[TBL] [Abstract][Full Text] [Related]
12. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma.
Lenzi R; Rosenblum M; Verschraegen C; Kudelka AP; Kavanagh JJ; Hicks ME; Lang EA; Nash MA; Levy LB; Garcia ME; Platsoucas CD; Abbruzzese JL; Freedman RS
Clin Cancer Res; 2002 Dec; 8(12):3686-95. PubMed ID: 12473577
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites.
Sola-Vera J; Miñana J; Ricart E; Planella M; González B; Torras X; Rodríguez J; Such J; Pascual S; Soriano G; Pérez-Mateo M; Guarner C
Hepatology; 2003 May; 37(5):1147-53. PubMed ID: 12717396
[TBL] [Abstract][Full Text] [Related]
15. Phase I dose-escalation study of tumor necrosis factor-alpha and concomitant radiation therapy.
Hallahan DE; Vokes EE; Rubin SJ; O'Brien S; Samuels B; Vijaykumar S; Kufe DW; Phillips R; Weichselbaum RR
Cancer J Sci Am; 1995; 1(3):204-9. PubMed ID: 9166477
[TBL] [Abstract][Full Text] [Related]
16. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites.
Salerno F; Merli M; Riggio O; Cazzaniga M; Valeriano V; Pozzi M; Nicolini A; Salvatori F
Hepatology; 2004 Sep; 40(3):629-35. PubMed ID: 15349901
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a standardized protocol of intracavitary recombinant interferon alpha-2b in the palliative treatment of malignant peritoneal effusions. A prospective pilot study.
Sartori S; Nielsen I; Tassinari D; Trevisani L; Abbasciano V; Malacarne P
Oncology; 2001; 61(3):192-6. PubMed ID: 11574774
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer.
Wolf JK; Bodurka DC; Gano JB; Deavers M; Ramondetta L; Ramirez PT; Levenback C; Gershenson DM
Gynecol Oncol; 2004 Aug; 94(2):442-8. PubMed ID: 15297186
[TBL] [Abstract][Full Text] [Related]
20. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.
Buller RE; Runnebaum IB; Karlan BY; Horowitz JA; Shahin M; Buekers T; Petrauskas S; Kreienberg R; Slamon D; Pegram M
Cancer Gene Ther; 2002 Jul; 9(7):553-66. PubMed ID: 12082455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
